Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Bioventus Inc. Class A Common Stock

BVS

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

Last trade $10.51
Day change +$0.045 (+0.43%)
Day range $10.15 – $11.21
Volume 247,015
Market cap $716M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$716.24M
Price / earnings
11.93×
Price / book
2.98×
Price / sales
1.22×
EV / sales
1.56×
EV / EBITDA
8.87×

Profitability

Earnings per share
$0.88
Return on assets
8.92%
Return on equity
24.97%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.96×
Current ratio
1.68×
Quick ratio
1.16×
Cash ratio
0.19×

Cash flow

Price / cash flow
8.19×
Price / free cash flow
8.43×
Free cash flow
$84.99M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BVS, quarterly periods
Line itemQ3 FY2026 Sep 26, 2026Q2 FY2026 Jun 27, 2026Q1 FY2026 Mar 28, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 27, 2025Q2 FY2025 Jun 28, 2025Q1 FY2025 Mar 29, 2025Q4 FY2024 Dec 31, 2024
Revenue$142.44M$153.21M$132.09M$157.9M$138.65M$147.66M$123.88M$153.64M
Cost of revenue$45.31M$47.54M$41.32M$49.12M$44.42M$45.57M$40.82M$50.99M
Gross profit$97.13M$105.67M$90.77M$108.78M$94.23M$102.09M$83.06M$102.66M
Selling, general and administrative$82.95M$82.74M$78.33M$82.76M$78.66M$79.11M$73.5M$86.87M
Research and development$3.44M$3.17M$2.47M$3.01M$2.92M$3.17M$3.01M$3.27M
Total operating expenses$87.43M$86.54M$82.35M$89.3M$82.98M$83.72M$78.11M$92.21M
Operating income$9.7M$19.13M$8.42M$19.49M$11.25M$18.37M$4.95M$10.45M
Interest expense-$3.76M-$4.07M-$4.33M$0-$6.18M-$7.49M-$7.51M$0
Income before taxes$6.16M$15.31M$4.52M$14.14M$4.67M$10.31M-$3.42M-$53K
Income taxes-$701K-$20.9M$571K-$3.18M$664K$1.04M-$95K$550K
Net income$6.86M$36.21M$3.95M$17.32M$4.01M$9.27M-$3.32M-$603K
Net income attributable to common shareholders$5.99M$36.21M$3.11M$14.76M$3.16M$9.27M-$2.64M-$388K
EBITDA$20.02M$29.66M$20.08M$33.42M$22.65M$30.42M$16.82M$22.8M
Basic earnings per share$0.09$0.49$0.05$0.22$0.05$0.11-$0.04-$0.01
Diluted earnings per share$0.08$0.47$0.04$0.20$0.05$0.11-$0.04-$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Bioventus (BVS) Matches Q3 Earnings Estimates

Bioventus (BVS) reported Q3 2026 earnings of $0.17 per share, matching consensus estimates, but revenues of $142.44 million missed expectations by 4.74%. The stock has gained 79.1% year-to-date, significantly outperforming the S&P 500's 10.7% gain. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. BioCryst Pharmaceuticals (BCRX) is expected to report results on November 4 with anticipated earnings of $0.10 per share, representing 66.7% year-over-year growth.

GlobeNewswire Inc.

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference

Bioventus Inc. announced that Mark Singleton, Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The presentation will be webcast live and available for replay on the company's investor website.

Benzinga

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Conexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.

GlobeNewswire Inc.

Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence

The global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market while Asia-Pacific is the fastest-growing region.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Mar 26, 2004$0.61Mar 31, 2004unknown
Dec 26, 2003$0.61Dec 31, 2003unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.